Veracyte 3Q 2026: Revenue $151.75M, EPS $0.38 — 10-Q Summary
Veracyte reported 3Q 2026 revenue of $151.75M, up 15% YoY, and net income of $0.38 per share, up 65%. Growth was driven by 13% test-volume growth and improved pricing. The company acquired Convergent Genomics, adding a bladder cancer testing platform.
How this was made
The 30-second read
Why it matters
The earnings beat could trigger short‑term buying pressure, but the modest scale limits broader market impact.
Market read
Primary earnings release for a small‑cap biotech; relevant for traders monitoring diagnostic testing stocks.
What to watch
The impact of the French subsidiary deconsolidation on future earnings could be material.
Background
Veracyte's 10‑Q filing provides the first public disclosure of its Q3 2026 financial results, including a notable acquisition of Convergent Genomics.
Ticker impact
Veracyte reported Q3 2026 revenue of $151.75M, up 15% YoY, and EPS of $0.38 in its 10‑Q filing.
potential modest upside as the market prices in stronger revenue growth
The company posted higher revenue and profit margins, driven by test‑volume growth and a recent acquisition, which could improve outlook.
Market effects
Diagnostic testing sector may see renewed interest from investors tracking biotech earnings trends.
U.S. biotech market could experience slight upward pressure.
Limited to investors focused on U.S. listed biotech firms.
Counterpoint
Revenue growth may be unsustainable without broader market adoption of new tests.
Key entities
- CompanyVeracyte, Inc.
U.S. listed molecular diagnostics company (ticker VCYT).
- CompanyConvergent Genomics
Acquired firm adding a urine‑based bladder cancer test platform.
